chemXplore tracks 145 projects in Spain, of which 40 are active.
Of the active ones, 28 new construction, 6 expansion and 4 revamp / retrofit.
8 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.
Industrial-scale project to capture about 1 million tCO₂/year at a Barcelona cement plant, combining capture, transport infrastructure and oxy‑combustion technologies.
Recurring profit €195.8m; EBITDA €491.5m and on track for €620m FY; Teréga stake acquired for €573m and Saggas stake deal for €31m; €1/share dividend maintained.
Q3 revenue rose >10% y/y and company remains on track for ~15–16% full‑year growth; Q3 net cash usage ≈ $28M with ≈ $134M cash on hand; margin improvement and an ~$8bn electrolyzer pipeline.
Agreement targets replacing fossil-fuel cogeneration with biomass, biomethane and e-fuels using biogenic CO2 for high-thermal industries.
Permanently sealed 13 wells with three plugs each, seabed cleared and site prepared for final abandonment of surface facilities.
Second client session presented CER business model, draft statutes and legal Q&A; links to WESHARE pilots in Antwerp and Getafe.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
Ten projects won awards across six categories for initiatives linking electrification, biodiversity and rural development, from industrial decarbonisation to community energy and journalism.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
active / all projects
